Rizatriptan
CHF 9.64
Auf Lager
SKU
9BPCD9N24IR
1 Verfügbar Details
Rizatriptan (Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT). Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan. Rizatriptan is available only by prescription in the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv) and Israel (as Rizalt).
30 Tage Rückgaberecht
GarantieWeitere Informationen
- Allgemeine Informationen
- GTIN 09786130968502
- Genre Chemie
- Editor Lambert M. Surhone, Mariam T. Tennoe, Susan F. Henssonow
- Anzahl Seiten 120
- Herausgeber Betascript Publishing
- Gewicht 159g
- Größe H220mm x B7mm x T150mm
- EAN 9786130968502
- Format Fachbuch
- Titel Rizatriptan
Bewertungen
Schreiben Sie eine Bewertung